Ixekizumab治疗中度银屑病4年持续高效安全:UNCOVER-3研究
UNCOVER-3研究评估推荐剂量Ixekizumab治疗中重度斑块状银屑病204周的疗效与安全性。第204周时,采用mNRI法,PASI 75/90/100应答率分别为82.8%、66.4%和48.3%;未发现新的安全性问题。
要点
- Ixekizumab治疗204周持续维持高PASI应答率。
- 第204周PASI 75/90/100(mNRI)分别为82.8%、66.4%、48.3%。
- 4年安全性特征与既往一致,无新发关注。
核心结论
- 持续Ixekizumab治疗4年可维持中重度斑块状银屑病的高疗效应答。
- 安全性特征与既往研究一致,未出现新的或意外安全性问题。
研究设计与样本
- UNCOVER-3为随机、双盲、多中心、3期研究。
- 患者接受安慰剂、IXE 80 mg Q2W、IXE 80 mg Q4W(起始160 mg)或依那西普50 mg每周两次。
- 第12周全部患者转为IXE Q4W进入长期扩展(264周)。
- 第60周后研究者可决定调整为IXE Q2W。
- 第204周疗效终点包括PASI 75/90/100、sPGA 0/1、PSSI=0、NAPSI=0、PPASI 100。
主要发现
- 第204周mNRI法PASI 75/90/100应答率分别为82.8%、66.4%、48.3%。
- 第204周as-observed法PASI 75/90/100分别为98.2%、87.8%、67.1%。
- 第204周MI法PASI 75/90/100分别为94.8%、73.3%、52.7%。
- sPGA(0,1)在as-observed、MI、mNRI法分别为88.7%、76.2%、68.5%。
- sPGA(0)在as-observed、MI、mNRI法分别为68.9%、54.6%、49.7%。
关键数值与推荐
- 第204周mNRI法PASI 75应答率82.8%。
- 第204周mNRI法PASI 90应答率66.4%。
- 第204周mNRI法PASI 100应答率48.3%。
临床怎么用
- 支持Ixekizumab长期用于中重度斑块状银屑病的持续管理。
- 长期治疗中可维持高PASI应答,安全性未见新信号。
局限性
- 疗效数据采用as-observed、MI和mNRI多种插补方法汇总,结果解读需注意方法差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis, a chronic disease usually requires long-term disease management. OBJECTIVE: This study evaluates the efficacy and safety of recommended ixekizumab (IXE) dose over 4 years (204 weeks) from UNCOVER-3 study. METHODS: UNCOVER-3 was a randomised, double-blind, multicenter, phase 3 study wherein patients with moderate-to-severe plaque psoriasis received placebo, IXE 80 mg every 2 weeks (Q2W), IXE 80 mg every 4 weeks (Q4W) (both IXE groups had 160 mg starting dose) or etanercept 50 mg twice weekly. At week 12, all patients switched to IXE Q4W dose for the long-term extension (264 weeks). After week 60 and at investigator's discretion, patients could receive dose adjustment to IXE Q2W. The efficacy endpoints at week 204 were percentage of patients achieving PASI 75/90/100, sPGA score of 1 or 0, and those achieving PSSI = 0, NAPSI = 0 and PPASI 100. Efficacy data were summarised through 204 weeks using as-observed, multiple imputation (MI) and modified non-responder imputation (mNRI) methods. RESULTS: The proportion of patients achieving PASI 75/90/100 at week 204 using mNRI method were 82.8%, 66.4% and 48.3%, respectively. Using as-observed and MI methods, 98.2% and 94.8% patients achieved PASI 75, 87.8% and 73.3% achieved PASI 90, and 67.1% and 52.7% achieved PASI 100 response, respectively, at week 204. The response rates for sPGA (0, 1) were 88.7%, 76.2% and 68.5% and for sPGA (0) were 68.9%, 54.6% and 49.7% using as-observed, MI and mNRI methods, respectively. Similar trends were observed with NAPSI = 0, PSSI = 0, PPASI 100 and itch NRS = 0. There were no new safety concerns through year 4. CONCLUSIONS: This study demonstrated sustained high-efficacy response through 4 years of continuous treatment with ixekizumab in patients with moderate-to-severe plaque psoriasis. The safety profile remained consistent with prior findings, with no new or unexpected safety concerns.
引用
- Lebwohl MG, Gordon KB, Gallo G, et al. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2019. PMID: 31479549. doi:10.1111/jdv.15921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。